Business Wire
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
📊
AI Sentiment
Positive
7/10
- Home
- NGNE
NGNE
Neurogene Inc.
as of 03-12-2026 3:28pm EST
$22.28
$0.97
-4.17%
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 327.8M | IPO Year: | 2014 |
| Target Price: | $60.13 | AVG Volume (30 days): | 157.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.88 - $37.27 | Next Earning Date: | N/A |
| Revenue: | $925,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -7.41 | Index: | N/A |
| Free Cash Flow: | -71411000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Neurogene Inc. (NGNE)
Cvijic Christine Mikail
Sell
President and CFO
NGNE Feb 27, 2026
Avg Cost/Share
$25.11
Shares
4,800
Total Value
$120,526.08
Owned After
109,843
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | NGNE | President and CFO | Feb 27, 2026 | Sell | $25.11 | 4,800 | $120,526.08 | 109,843 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 13, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 13, 2025 · 100% conf.
AI Prediction SELL
1D
-2.29%
$25.88
Act: -13.84%
5D
-5.83%
$24.95
Act: -22.99%
20D
+1.67%
$26.93
Act: -20.99%
Price: $26.49 Prob +5D: 0% AUC: 1.000
0001404644-25-000103
ngne-202511130001404644FALSE00014046442024-03-182024-03-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 13, 2025
Neurogene Inc. (Exact name of registrant as specified in its charter)
Delaware 001-3632798-0542593
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
535 W 24th Street, 5th Floor New York, NY 10011 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (877) 237-5020
N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.000001 par valueNGNEThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02Results of Operations and Financial Condition
On November 13, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on November 13, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Item 2.02 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Description
99.1 Press Release dated November 13, 2025
99.2Corporate Presentation (November 13, 2025)
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NEUROGENE INC.
Date: November 13, 2025By:/s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 11, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 11, 2025
0001404644-25-000082
ngne-202508110001404644FALSE00014046442024-03-182024-03-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 11, 2025
Neurogene Inc. (Exact name of registrant as specified in its charter)
Delaware 001-3632798-0542593
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
535 W 24th Street, 5th Floor New York, NY 10011 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (877) 237-5020
N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.000001 par valueNGNEThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02Results of Operations and Financial Condition
On August 11, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Item 2.02 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Description
99.1 Press Release dated August 11, 2025
99.2Corporate Presentation (August 11, 2025)
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NEUROGENE INC.
Date: August 11, 2025By:/s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer
2025 Q1 Q1 2025 Earnings
8-K May 9, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 9, 2025
0001404644-25-000044
ngne-202505090001404644FALSE00014046442024-03-182024-03-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 9, 2025
Neurogene Inc. (Exact name of registrant as specified in its charter)
Delaware 001-3632798-0542593
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
535 W 24th Street, 5th Floor New York, NY 10011 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (877) 237-5020
N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.000001 par valueNGNEThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02Results of Operations and Financial Condition
On May 9, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Description
99.1 Press Release dated May 9, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NEUROGENE INC.
Date: May 9, 2025By:/s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer
Latest Neurogene Inc. News
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
Compare NGNE vs Leading Stocks
See how NGNE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.